SCHEMBL30735609

SCHEMBL30735609

Fc1ccc(C2CCNCC2)c2ccncc12

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
RPS6KA3 P51812 1/20 0.51
MKNK1 Q9BUB5 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
SLC6A2 P23975 11/20 0.43
SLC6A4 P31645 11/20 0.43
HTR1A P08908 10/20 0.43
SLC6A3 Q01959 7/20 0.40
KCNH2 Q12809 1/20 0.39
TLR9 Q9NR96 1/20 0.39
TLR8 Q9NR97 1/20 0.39
TLR7 Q9NYK1 1/20 0.39
HTR6 P50406 1/20 0.39
APP P05067 2/20 0.38
CCNT1 O60563 1/20 0.38
CDK9 P50750 1/20 0.38
HTR2C P28335 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19284557 1.00 RPS6KA3 (0.51) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL19297102 0.94 RPS6KA3 (0.51) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL30735615 0.94 RPS6KA3 (0.51) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL30735800 0.82 RPS6KA3 (0.42) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL19297189 0.82 RPS6KA3 (0.42) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL19297029 0.81 HTR2C (0.50) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL30735696 0.81 HTR2C (0.50) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4
SCHEMBL30735567 0.79 HTR6 (0.54) SLC6A2SLC6A4HTR1ASLC6A3HTR6
SCHEMBL19284720 0.79 HTR6 (0.54) SLC6A2SLC6A4HTR1ASLC6A3HTR6
SCHEMBL19297111 0.79 RPS6KA3 (0.42) RPS6KA3MKNK1MKNK2SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 SRX CARDIO, LLC (US) 2024-02-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891369-B2 Compounds for binding proprotein convertase subtilisin/kexin type 9 PCSK9, PCSK6, PCSK7 RPS6KA3 2059/4885MKNK1 794/4885MKNK2 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.